Capsugel announced today the launch of its Dosage Form Solutions (DFS) business unit to address growing customer demand for innovative product development and commercial manufacturing in the healthcare industry. The DFS business unit will focus on the company’s growing expertise in lipid-based formulations, while continuing to expand its offerings in targeted release capsules.
“With the launch of the new DFS business unit, Capsugel builds on its heritage of delivering innovative, quality products and services in hard capsules, by advancing our expertise in product formulation and commercial finished product manufacturing,” said Guido Driesen, President & CEO of Capsugel. “DFS is well-positioned to help address our customers’ most pressing dosage form challenges of existing and new nutritional and pharmaceutical products.”
Amit Patel will serve as President of the DFS business unit from Capsugel’s headquarters in Morristown, N.J. Amit has extensive experience in the pharmaceutical industry, including generics and specialty pharmaceuticals. “Continuing to innovate and develop cutting-edge healthcare products is essential to maximizing the potential of the industry,” said Mr. Patel. “The DFS business unit uses our proprietary technology platforms to help bring improved products to the market faster for our customers. The platforms can enable various solid oral dosage product improvements including bioavailability enhancement, optimal dosing for potent APIs, controlled release, stability improvement and taste masking.”
Over the past decade, Capsugel has developed a world-class portfolio of products, technologies, and intellectual property. DFS will leverage its proprietary technology platforms of lipid-based formulations and targeted release capsule formulation, R&D capabilities and commercial manufacturing infrastructure to develop and manufacture products for customers. The business unit has operating sites in North America, Europe and Asia, and has been involved with hundreds of products and projects for leading and emerging specialty, branded and generic pharmaceutical customers, as well as those in the consumer health and nutritional segments.